Nvwm LLC Sells 2,244 Shares of Zoetis Inc. $ZTS

Nvwm LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 14.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,470 shares of the company’s stock after selling 2,244 shares during the quarter. Nvwm LLC’s holdings in Zoetis were worth $2,101,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after purchasing an additional 189,287 shares during the period. Polen Capital Management LLC lifted its holdings in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Northern Trust Corp boosted its position in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after acquiring an additional 78,508 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Zoetis by 4.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,252,697 shares of the company’s stock worth $700,207,000 after acquiring an additional 174,119 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $119.81 on Friday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock has a market cap of $53.10 billion, a PE ratio of 20.62, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The stock’s fifty day simple moving average is $144.93 and its two-hundred day simple moving average is $152.78. Zoetis Inc. has a 1-year low of $119.06 and a 1-year high of $181.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the previous year, the company earned $1.58 earnings per share. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is presently 33.67%.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Stifel Nicolaus set a $140.00 price target on Zoetis in a research report on Tuesday. Argus reaffirmed a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. UBS Group decreased their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $191.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.